Charles Jillings, CEO of Utilico, energized by strong economic momentum across Latin America. Watch the video here.
Most importantly to everyone here, have conviction in your investment and remember the reasons you invested in the first place and don't let anyone influence your decision.
Like every board, when theres a big RNS, the board goes to absolute s**t with new users spreading doubt either in their attempt to get cheaper entry themselves, or just through jealously for missing the boat.
HODL!
Hope you're right Chris for your sake. Paul was doing the same at 210p, 140p and 65p and encouraging everyone to buy all the way down to 40p (and still is). Sometimes wise to take the blinkers off and take a step back not to become too emotionally involved.
Is possible that its a MM shake this morning, but a lot of people will just want to get out of this stock and get their money back to avoid a repeat of other companies who have gone into liquidation despite a promising future. The cash is a massive concern and they won't risk it going down to the wire - they will get money any means possible to keep the lights on and shareholders always get shafted.
Basically TR1 to be RNS'ed soon (however some past TR1s haven't been), data to be released within the next 2 weeks, Consilium to lead the media story. License deal to follow to validate to the wider market and make funds realise there won't be a fundraise (at least not on LSE at these levels) so they will have to buy on the open market - due to their internal policies they will need data release to justify taking positions. Money generated can allow Avacta to push on with Ava3996 through the clinic which can absolutely dwarf ava6000 which is just the quickest route to market.
IMO the company that will do a license deal will eventually be our acquirer when further data is generated and "derisks" it even further for their own board and shareholders, look up how Genetech did it.
@IFA90 - People were removed if they didn't prove they were a shareholder which is totally fair.
In another share 2 years ago I helped organise a call between telegram members which had a group of 450 people with the CEO of a company at the time. Helped massively improve PI sentiment asking questions and everything remained within the NOMAD rules with no price sensitive information being discussed. Just adds a lot of colour / clarity to things previously discussed. We went onto hold 4 more calls over the following year and it helped build a bridge between the company and PIs outside of the standard communication channels like with investormeet etc.
When these Telegram groups often hold significantly more shares combined than any institutions, its very reasonable to have dialogue with the company.
Not so sure that they are planning on selling it.. a spin off would mean you the company gets split and you get an equal number of shares in the Dx division as you keep in the Tx division. Been in a company who did this before.
Could very well be that another player wants to enter the market and they see us as the perfect bolt on to their company. Therefore they buy a part of the Dx division for cash, take a % of the company and keep it on AIM and we still have shares in it. Win win for Al parties involved.
Shambles how Trinity broker note hasnt changed their chance of success from before ava6000 entered the clinic compared to now when Al yesterday said “Pre|CISION works”.
However someone raised a good point elsewhere that it will be remaining the same right now until data release from a legal point of view so no judgement was used on their part and 10% would be used as a industry standard value for a drug. Once data is out / officially in P2 then they will increase their COS.
One of the easiest holds you'll ever have when the value disconnect is so stark. Value always shines through eventually, just a bit more patience is required.
Let’s not take that out of context Viking. That was in regard to getting funds onboard given we are at P1a, and need to be seen as attractive compared to others on the market.
Now p1b isn’t required and it’s going to be a pivotal p2 so no p3 needed, that’s accelerated timelines significantly. Could be making billions in rev within 2 years (if we are even still caked Avacta by then)
@Doggy100 There was a post a few years ago on another forum by a "troll, shorter, deramper" whatever you want to call them, and they came out and said they were being paid by companies to keep the share price low. Some of those companies were actually short and hired people to help. Other companies were actually long, but the amount of money they look to buy in they need a negative narrative to help get a lower buy in price, once they have it the negative commentary stops
It might be Labor Day but £10k just bought at 108 haha
Great meeting some of you today, didn’t manage to talk to everyone but some great conversations particularly with Al post AGM for drinks!
Couple of things, there isn’t anyone from cohort 1 still getting treatment, wouldn’t be drawn if cohort 2 is but I took it as a yes. More of what he wasn’t sure if he was allowed to say they are but did confirm that the middle number onwards from the original cohorts were so that’s 2-3+.
He reiterated that there is no fundraise in the immediate nor short term and that they certainly wouldn’t be looking at doing a placing under £1.
There will likely be a couple of clinicians talking about the data at the end of P1a and in his opinion it will go to cohort 7. Regarding media the angle that they will be going for is quality of life, purely because these are terminally ill patients but the quality of life they have has been significantly improved so that’s a angle the media can run for.
Briefly mentioned about the higher the dose could really have a positive impact and blast the tumour so definitely why they have no idea on the recommended dose for the next stage yet.
Towards the end when talking about partnering, he couldn’t say much at all but from what he did say there are ongoing talks 100% (with a big pharma) and it sounded positive.
Came away from it the most confident have ever been, but it will take some patience as they extend through the cohorts but this ultimately drives the share price.
Also he said about the p1b design right now, he would be surprised if it went ahead in the same format. I’m sure someone else can confirm what exactly he said word for word but don’t be surprised to see it changed as more data is available.
Also said that the timeline for p1b could be driven down significantly if they go for weekly dosing.
The issue is if one clinician thinks it’s a great idea on weekly dosing and another thinks every few weeks is best, to be decided nearer the time.
@ipadtrader Any thoughts on who would be the best candidate to replace STFL?
From what it seems, STFL have managed this horribly and floated the idea of the placing to get cheap shares into their city friends pockets. Avacta need a backbone to stand up and tell them to f*** off and actually do their job
Good spot Mack. On Sharepad the 200k has been modified to 106,097, so yes it certainly seems like it was their last batch to get rid of until their next lot in July.
Hopefully can get a bounce tomorrow and some news flow in the next few weeks.
@cj62 " what happens if they can't find the MTD ?"
47:05 on this link, explains exactly what happens if they cant find a MTD.
https://youtu.be/VwH1OYGgVJM
just put 12ft.io/ before the https bit, and thats your paywall hop across most sites :)
Yep. Looking in fantastic shape.
"That included a £4m one off outflow for investment which is not part of operating cash flow. The underlying burn is £11m per annum."
So funded through to Q1/2 2023 before they even need to think about funds. Puts them in a great position negotiating for licensing deals.
Simply add on any dips and hold.
Agree with your post Geordie.
What I will add is that "10% growth from
£50m to £55m" excludes Omicron and Malaria. So maybe it's wise what they've done in the short term to add lower growth then once the likes of Omicron is online then they can issue a trading update with a revised forecast. Worst thing to happen would say project £90m which includes Omicron then for a bump along the road and disappoint the market.
Mo is under promise and over deliver which he told me at the AGM.
Very safe play at these levels just frustratingly more patience required
Yes very positive. Good to see they have done this as it was mentioned at the AGM. Big pharma know Hvivo rather than Open Orphan and all the media over the pond is Hvivo..
Aldebaran is a known shorter, just ignore him, filter or whatever you want to do and don't give him any airtime by responding to posts.
Very positive that Mo is having a positive impact to investment firms, and any presentations to them have gone down well. Hopefully get a sticky shareholder base again...
https://t.co/zk5lQeksRP
No the covid test hasn't been abandoned.
Al at the AGM said the following:
"Quite a lot of products on the market dont perform well enough around specificity, so cross react with other things, and quite often also sensitivity.
Big opportunity to develop market leading tests using Affimer tech, competitor advantage. Not a lot of public information, but I can assure you theres a huge amount of work going on, developing respiratory infection, covid, hormones, vitamins, interesting areas, a lot small molecule tests (negative read assays), very difficult for a consumer to read, we can flip it to positive read tests, theres an angle for Affimer platform to develop really competitive tests"
Later went onto say conservatively going to say covid test rev will be next year. Based on its very quick to identify an Affimer to bind to the variant, but it comes down to regulatory approval. Will be with regulators this year. Wont give a timeline. UK outside of covid dose provide a quicker route to market
Come on guys, dont build it up to only be disappointed later. RSP looks healthy on the bid but equal amounts on the ask. Only plays into the traders hands.